Daiichi Sankyo Logo PNG
Developing medications requires time, laboratory research, and clinical trials before a drug becomes available to patients. The Daiichi Sankyo logo is associated with a pharmaceutical company that develops and manufactures medications, including treatments for complex diseases.
Daiichi Sankyo was founded in 2005 after the merger of Sankyo and Daiichi Pharmaceutical. The purpose of the merger was to strengthen Japan’s position in the global pharmaceutical market. Sankyo began operations in 1899 in Tokyo, producing traditional medicines and vitamins. By the mid-20th century, the company became known for developing antibiotics and vaccines, including colivaccine, released in 1963. In the 1970s, the main focus shifted to drugs for the treatment of cardiovascular diseases.
Daiichi Pharmaceutical was established in 1915 in Osaka. Initially, the enterprise produced chemicals for pharmaceutical companies. After World War II, it focused on developing antibiotics and anti-inflammatory agents. In 1970, the company introduced cephalosporin antibiotics and, in the 1980s, expanded its product line to include medicines for hypertension and diabetes.
After the merger in 2005, Daiichi Sankyo became Japan’s largest pharmaceutical company, with annual revenue of about one trillion yen. In 2006, the international promotion of the drug Effient began in collaboration with Eli Lilly. In 2007, the company acquired the Indian pharmaceutical company Ranbaxy Laboratories for $ 4.6 billion. The goal of the deal was to expand the generics business, but the project ended in losses and the sale of assets in 2014.
Since 2013, the company’s activities have increasingly focused on oncology. Collaboration with AstraZeneca led to the development of the drug Enhertu, which received FDA approval in 2019 for the treatment of breast cancer. In 2020, the partners signed an agreement worth up to 13 billion dollars to expand their oncology portfolio.
In the years that followed, Daiichi Sankyo developed antibody-drug conjugate technologies. The company invested in new plants and scientific research.
The company strengthened its position as a global leader in oncology and cardiology, building a portfolio of more than 10 innovative drugs.
Meaning and History
What is Daiichi Sankyo?
It is a major Japanese pharmaceutical corporation with a broad international network and a strong research base. The company develops, manufactures, and distributes drugs for the treatment of oncological, cardiovascular, thrombotic, and other chronic diseases, as well as vaccines, over-the-counter medicines, and cosmetic products. Its subsidiaries operate in the United States and Europe, and its main areas of development are innovation in medicine and oncology research. The corporation’s portfolio includes well-known brands such as Ranbaxy, American Regent, and Plexxikon.
2005 – today
After the merger of the Japanese pharmaceutical giants “Daiichi Pharmaceutical” and “Sankyo Company, Limited” into a single structure, a brand named “Daiichi Sankyo” appeared. In Japanese, “Daiichi” means “number one.” At the same time, “Sankyo” is made from the words “three” and “together,” suggesting partnership. The new name symbolically connected the heritage of both companies, emphasizing their equal contribution to the creation of the combined enterprise.
The Daiichi Sankyo symbol itself is circular, with the color transitioning from deep blue at the bottom to green and yellow at the top. In the center, in the negative space between the two shades, a white form resembling a drop or an abstract cutout appears. Visually, the emblem resembles a sphere reflecting the sky and the sun, conveying a sense of open space or of a globe. However, the image carries several associations, from analogies with molecules and biological processes to the idea of continuous research and transformation in medicine and the pharmaceutical industry. The blue tone conveys a scientific and medical tone, strengthening the brand’s association with serious scientific work.
Below the circular symbol is the company name, written in a serif typeface. The name “Daiichi-Sankyo” is set in lowercase letters, with only “D” and “S” remaining uppercase. An interesting accent is the diamond that replaces the standard dot above the letter “i” in the word “Daiichi.”
The new Daiichi Sankyo logo reflects an equal partnership and a shared strategy for development in medical research and pharmaceuticals.
